Senín A, Broquetas T, Lens S, Cañete N, Londoño María-Carlota, Ferraro M, Forns X, Salar A, Carrión JA

Language: English
References: 20
Page: 312-317
PDF size: 189.16 Kb.

ABSTRACT

The addition of the new protease inhibitors (PIs) to peg-interferon (IFN) and ribavirin (RBV), approved for chronic hepatitis C, has clearly improved sustained virological response (SVR) rates although several adverse events have been reported with this regimens, including mild hematological toxicity. Moreover, severe pancytopenia and aplastic anemia during triple therapy with telaprevir has recently been described in seven patients. We report here two cases of severe agranulocytosis/aplastic anemia using boceprevir or simeprevir in interferon-based combination and 2 additional cases of severe myelosupression in IFN-free therapy with sofosbuvir and simeprevir plus RBV. Our observations suggest that PIs could have a sort of class-effect in developing severe hematologic toxicity or, at least, an additive interaction with other potentially myelotoxic agents such as IFN or RBV that are used in the classical regimens against HCV. Unfortunately, the mechanisms behind this phenomenon are currently unknown. In conclusion, given the lifethreatening character of these complications, close monitoring is mandatory in patients under PIs based therapy to promptly detect serious hematological toxicities and to carefully evaluate treatment discontinuation. Prospective studies assessing the usefulness of RBV in the era of new IFN-free combinations are needed.

REFERENCES

1. 1 McHutchison JG, Manns MP, Muir AJ, Terrault NA, Jacobson IM, Afdhal NH, Heathcote EJ, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010; 362: 1292-303.

2. European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: Management of hepatitis C virus infection. J Hepatol 2013; 63: 199-236.

3. Ioannou S, Hatzis G, Vlahadami I, Voulgarelis M. Aplastic anemia associated with interferon alpha 2a in a patient with chronic hepatitis C virus infection: a case report. J Med Case Rep 2010; 4: 268.

4. Hoffmann A, Kirn E, Krueger GR, Fischer R. Bone marrow hypoplasia and fibrosis following interferon treatment. In Vivo 1994; 8: 605-12.

5. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-16.

6. Poordad F, McCone JJr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-2206.

7. Lens S, Calleja JL, Campillo A, Carrion JA, Broquetas T, Perello C, de la Revilla J, et al. Aplastic anemia and severe pancytopenia during treatment with peg-interferon, ribavirin and telaprevir for chronic hepatitis C. World J Gastroenterol 2015; 21: 5421-6.

8. Hézode C, Fontaine H, Dorival C, Larrey D, Zoulim F, Canva V, de Ledinghen V, et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol 2013; 59: 434-41.

9. Londono MC, Perello C, Cabezas J, Canete N, Lens S, Marino Z, Gambato M, et al. The addition of a protease inhibitor increases the risk of infections in patients with hepatitis C-related cirrhosis. J Hepatol 2015; 62: 311-16.

10. Ogawa E, Furusyo N, Kajiwara E, Nomura H, Kawano A, Takahashi K, Dohmen K, et al. Comparative safety study on severe anemia by simeprevir- versus telaprevir-based triple therapy for chronic hepatitis C. J Gastroenterol Hepatol 2015; 30: 1309-16.

11. De Franceschi L, Fattovich G, Turrini F, Ayi K, Brugnara C, Manzato F, Noventa F, et al. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology 2000; 31: 997-1004.

12. Canonico PG, Kastello MD, Spears CT, Brown JR, Jackson EA, Jenkins DE. Effects of ribavirin on red blood cells. Toxicol Appl Pharmacol 1984; 74: 155-62.

13. Miura Y, Kami M, Yotsuya R, Toda N, Komatsu T. Pure redcell aplasia associated with pegylated interferon-alpha-2b plus ribavirin. Am J Hematol 2008; 83: 758-9.

14. Tanaka N, Ishida F, Tanaka E. Ribavirin-induced pure red-cell aplasia during treatment of chronic hepatitis C. N Engl J Med 2004; 350: 1264-5.

15. Fellay J, Thompson AJ, Ge D, Gumbs CE, Urban TJ, Shianna KV, Little LD, et al. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature 2010; 464: 405-8.

16. Cusato J, Allegra S, De Nicoló A, Boglione L, Fatiguso G, Mohamed Abdi A, Cariti G, et al. Intracellular and Plasma Trough Concentration and Pharmacogenetics of Telaprevir. J Pharm Pharm Sci 2015; 18: 171-6.

17. Lupo F, Russo R, Iolascon A, Ieluzzi D, Siciliano A, Toniutto P, Matté A, et al. Protease inhibitors-based therapy induces acquired spherocytic-like anemia and ineffective erythropoiesis in chronic HCV patients. Liver Int 2016; 36: 49-58.

18. Lawitz E, Sulkowski MS, Ghalib R, Lawitz E, Sulkowski MS, Ghalib R, Rodriguez-Torres M, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014; 384: 1756-65.

19. Romero-Gómez M, Berenguer M, Molina E, Calleja JL. Management of anemia induced by triple therapy in patients with chronic hepatitis C: challenges, opportunities and recommendations. J Hepatol 2013; 59: 1323-30.

20. Carrión JA, Gonzalez-Colominas E, García-Retortillo M, Cañete N, Cirera I, Coll S, Giménez MD, et al. A multidisciplinary support programme increases the efficiency of pegylated interferon alfa-2a and ribavirin in hepatitis C. J Hepatol 2013; 59: 926-33.